QNRX
Quoin Pharmaceuticals, Ltd.
NASDAQ · Healthcare · Biotechnology · US
$7.06
+0.71%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$6.98
From 52W high−68.34%
Volume14769.00
Market cap$14.18M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$6.98
From 52W high
−68.34%
Volume
14769.00
Market cap
$14.18M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
63.9
MomentumView details →
1D Return
+0.71%
YTD Return
−50.81%
SummaryUpdated Jun 1, 2026
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) is a specialty pharmaceutical company founded in 2016 and based in Ashburn, Virginia. The company focuses exclusively on developing therapeutic products for rare and orphan diseases, particularly rare skin conditions that affect small patient populations with significant unmet medical needs. Since its initial public offering in August 2016, Quoin has concentrated its efforts on advancing a pipeline of topical treatments through clinical development, with its lead candidate targeting Netherton Syndrome, an extremely rare genetic skin disorder.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration granted Rare Pediatric Disease designation to Quoin Pharmaceuticals' QRX003 for the treatment of Peeling Skin Syndrome, the second such designation for the drug after a prior one for Netherton Syndrome.12d agoQuoin Pharmaceuticals announced positive clinical trial results for its product on Friday morning.23d agoQuoin Pharmaceuticals entered into a securities purchase agreement with healthcare-focused institutional investors to raise up to approximately $50.0 million in gross proceeds through a private placement of ordinary shares and warrants.23d ago